Skip to main content

Pablo Gabriel Medina

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Pablo Gabriel Medina

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Funciones Alternativas de la Sex Hormone-Binding Globulin: Mecanismos Moleculares y Papel en Fisiología y Fisiopatología

IP: David Martinez Selva
Collaborators: Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina, Pilar Costa Forner
Funding agency: Instituto de Salud Carlos III
Funding: 190000
Reference: PI23/00544
Duration: 01/01/2024 - 31/12/2026

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: -
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Estudio de quasispecies por metagenómica en neuropatías asociadas a virus por secuenciación masiva de nueva generación.

IP: Josep Quer Sivila
Collaborators: Sergi Colomer Castell, Marta Ibañez Lligoña, Lluís Viladomiu Catà, Damir Garcia Cehic, Maria Piñana Moro, Pablo Gabriel Medina, Arnau Llauradó Gayete, Carolina Campos Martinez, Alejandra Gonzalez Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 292820
Reference: PI22/00258
Duration: 01/01/2023 - 31/12/2025

Mecanismos moleculares que regulan la sex hormone- binding globulin y sus implicaciones terapéuticas.

IP: David Martinez Selva
Collaborators: Lidia Fuertes Rioja, Maria Teresa Salcedo Allende, Lorena Ramos Pérez, Pablo Gabriel Medina
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI18/00320
Duration: 01/01/2019 - 31/12/2022

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Victoria López Craver

Victoria López Craver

Psychiatry, Mental Health and Addictions
Read more
Andrea Nieto I Brocal

Andrea Nieto I Brocal

Medium Grade Technician
Human Resources Directorate
Read more
Angel Michael Ortiz Zúñiga

Angel Michael Ortiz Zúñiga

Predoctoral researcher
Diabetes and Metabolism
Read more
Paula Granado Martinez

Paula Granado Martinez

Postdoctoral researcher
Biomedical Research in Melanoma
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.